Major depression is a debilitating psychiatric illness that is typically associated with low mood, 4 3 anhedonia and a range of comorbidities. Depression has a heritable component that has remained 4 4 difficult to elucidate with current sample sizes due to the polygenic nature of the disorder. To 4 5 maximise sample size, we meta-analysed data on 807,553 individuals (246,363 cases and 561,190 4 6 controls) from the three largest genome-wide association studies of depression. We identified 102 4 7 independent variants, 269 genes, and 15 gene-sets associated with depression, including both genes 4 8 and gene-pathways associated with synaptic structure and neurotransmission. Further evidence of the 4 9 7 1 expensive. The results of Howard, et al. 5 showed that there is a strong genetic correlation (r G = 0.86, 7 2
to derive a larger sample (127,552 cases and 233,763 controls) than studied previously. The PGC 1 0 1 analysis 9 included the 23andMe_307k discovery cohort and an earlier data release of the UK Biobank 1 0 2 cohort (n = 29,740, 14,260 cases and 15480 controls); we therefore obtained results from the PGC that 1 0 3 excluded both of these cohorts (termed "PGC_139k"; 43,204 cases and 95,680 controls). We sought replication of the variants associated with depression within a set of 23andMe participants 1 0 5 independent of the 23andMe_307k cohort included in the meta-analysis (474,574 cases of self- traits. The meta-analysis results were also used to identify a set of associated genes and gene-1 1 0 pathways, as well as enrichment of functional annotations associated with depression. Combining 1 1 1 evidence of enrichment in biological pathways with information on traits correlated with depression 1 1 2 allows for additional inferences about shared aetiological mechanisms, thereby increasing the utility 1 1 3 of the standard association analysis approach. Interactions between associated genes and available 1 1 4 drug treatments were also examined to identify novel drug treatments for depression. We conducted a genome-wide association meta-analysis of depression using 807,553 individuals 1 1 8 (Table 1; 246,363 cases and 561,190 controls) from three previous studies of depression, after 1 1 9 removing sample overlap; the previous studies were Hyde, et al. 8 Howard, et al. 5 , and Wray, et al. 9 .
We tested the effects of 8,098,588 genetic variants on depression and identified 9,744 associated 1 2 1 variants (P < 5 × 10 -8 ) of which 102 variants in 101 loci were independently segregating 1 2 2 (Supplementary Table 1 ). The basepair positions of these loci were identified by clumping all 1 2 3 associated variants (linkage disequilibrium r 2 < 0.1 across a 3 Mb window) and then merging any 1 2 4 overlapping clumps. Independent variants in each locus were identified through conditional analysis 10 1 2 5 using all variants in that locus. A Manhattan plot of our meta-analysis results is provided in Figure 1 with a quantile-quantile plot 1 2 7 provided in Supplementary Figure 1 . Linkage Disequilibrium Score (LDSC) regression 11 produced a 1 2 8 genomic inflation factor (λ GC ) estimate of 1.63 with an intercept of 1.015 (0.011) prior to inflation 1 2 9 correction, indicating that the inflation was due to polygenic signal and unlikely to be confounded by 1 3 0 population structure. All of the 102 associated variants had the same direction of effect on depression 1 3 1 across the three contributing studies and also within an independent replication sample of 1,507,153 1 3 2 individuals (Table 1 ; 474,574 cases and 1,032,579 controls). In the replication sample, 97 out of the 1 3 3 102 associated variants were nominally significant (P < 0.05) and 87 were significant after Bonferroni to depression). To determine whether causal relationships exist between depression and the 41 1 7 9 genetically correlated traits in Supplementary Table 3 , we used a bi-directional, two-sample 1 8 0
Mendelian randomisation (MR) approach using MR-Base v0.4.9 16 in R and an inverse-variance 1 8 1 weighted (IVW) regression analysis. Where there was also evidence of variant heterogeneity 1 8 2 additional sensitivity tests were conducted using an MR Egger test and a weighted median test 1 8 3
( Supplementary Table 4 ). A number of causal relationships were not tested because of sample overlap, which can lead to biased 1 8 5 effect size estimates 17 , or where there were an insufficient number of instrumental genetic variables 1 8 6 (n variables < 30). A total of 33 causal effects were tested, of which 24 were for a causal effect of 1 8 7 depression on another trait, and nine tests for a causal effect of another trait on depression. Directional 1 8 8 horizontal pleiotropy, where a genetic variant has an effect on both traits but via differing biological 1 8 9 pathways, can bias the estimates of causal effects between traits 18 . Using the MR Egger intercept test, 1 9 0 there was no evidence (P ≥ 0.05) of directional horizontal pleiotropy for any of the 33 causal effects action has been reported for dopamine reuptake inhibitors and D2-receptor agonists in animal models 4 0 0 of depression 79 . Furthermore, the dopamine and noradrenaline reuptake inhibitor bupropion is 4 0 1 licensed for the treatment of depression 80 . 4 0 2
We also identified genes with associated medications which, although not aimed at treating 4 0 3 depression, may provide unpredicted drug benefits or adverse effects for those with the disorder. The Neuregulin 1 (NRG1) receptor ErbB4, found on GABAergic neurones, has been identified as a developing agents, such as basimglurant and fenobam, as antidepressants and anxiolytics that target compounds have also been found to have antidepressant effects in rodent models of depression 84 .
Further, our work highlights other potential druggable genes associated with depression which are not, The principal strength of this study is the increased power obtained from the analysis of three large 4 3 2 independent cohorts. This has allowed the examination of the effects of variants and regions that have been identified previously to determine whether they maintain an effect on depression. We have used 4 3 4
variant-based analyses to calculate heritability enrichment across different brain regions and then also To conduct our analyses we included data from three previous studies of depression 5, 8, 9 . For the UK 4 5 3
Biobank study 5 slightly different quality control was applied and the data were reanalysed. For the 4 5 4
other two studies the summary statistics were obtained directly from the respective authors. Further 4 5 5
information regarding each of these cohorts is provided below. The population-based UK Biobank cohort 89 consists of 501,726 individuals with genome-wide data 4 5 8
for 93,095,623 autosomal genetic variants imputed using the HRC and UK10K reference panels 90 .
5 9
We used the variants from the HRC reference panel to conduct a 4-means clustering approach and coded as 1). β was the matrix of fixed effects, including sex, age, genotyping array, and the first 8 4 9 0 principal components and X was the corresponding incidence matrices. ) ( y y − was a vector of and Schielzeth 101 ). PRS were split into deciles and the odds ratio for MDD in each decile calculated 5 7 0 using the 1st decile as the reference group. We calculated genetic correlations using LDSC regression 11 and the online software LD hub if the χ 2 statistic is replaced with the product of 2 z-scores from 2 traits of interest 102 . Genetic correlations were calculated between the three datasets that contributed to the meta-analysis. Genetic correlations were also calculated between our meta-analysed results (23andMe_307k, UK Biobank sizes. Using multiple genetic variants can increase the strength of the instrument, but also increases 5 9 0 the risk of violating the MR assumptions.
9 1
We performed bidirectional, two-sample MR between our meta-analysis results for depression and all 5 9 2 available traits which had a significant genetic correlation with depression (identified in the previous 5 9 3 section). Traits directly related to or including depression (major depressive disorder, depressive 5 9 4 symptoms and PGC cross disorder) were excluded due to potential bias. The genetic instruments for 5 9 5
depression consisted of the independent, genome-wide significant variants, their effect sizes and 5 9 6 standard errors, as estimated in our genome-wide meta-analysis. Summary statistics from genome- wide association studies for the other traits were sourced from either publicly available datasets or 5 9 8 from the MR-Base database 16 . Overlapping datasets for the exposure and the outcome can lead to 5 9 9
bias and inflation of causal estimates 17 . To mitigate this, when the source of the other trait included 6 0 0 UK Biobank, 23andMe or any of the studies that contributed to PGC_139k, these studies were 6 0 1 removed from our meta-analysis of depression; for example, the neuroticism trait from van den Berg, association study of the other trait then an alternative study was sought for that other trait. All analyses were performed using the MR-Base "TwoSampleMR" v0.4.9 package 16 in R. To avoid 6 0 6 bias in the MR estimates due to linkage disequilibrium (r 2 ), clumping was applied using the 6 0 7
"clump_data" function with an r 2 < 0.001. Genetic variants were required to be available in both the 6 0 8 exposure and outcome traits and were harmonised using the default parameters within the weighted median test to examine whether the effect estimate was consistent. The principal MR test of a causal effect was conducted using inverse-variance weighted (IVW) 6 2 5
regression. This method is based on a regression of the exposure and the outcome which assumes the 6 2 6
intercept is constrained to zero, and produces a causal estimate of the exposure-outcome association. Where there was no evidence of global horizontal pleiotropy (P ≥ 0.05) from the second analysis (see to assess whether significance was maintained. We tested the causal effect of depression on 24 other 6 3 4 traits, and the causal effect of 9 other traits on depression. We used stratified LDSC regression to estimate the SNP-based heritability of depression, using the 6 3 7
sample prevalence as the population prevalence (0.302), and then examined the heritability of annotations were also analysed for variants in four histone marks: H3K4me1, H3K4me3, H3K9ac and 6 4 7
H3K27ac and these were grouped into 9 cell type groups: central nervous system (CNS), 6 4 8 cardiovascular, connective tissue or bone, gastrointestinal, immune or hematopoietic, kidney, liver, pyramidal neurons). These brain cell-types were assessed in MAGMA using the default setting of 6 7 0 10,000 permutations with a Bonferroni correction (α = 0.05 / 7; P < 7.14 × 10 -3 ) used to assess 6 7 1 significance.
7 2
Drug -gene interactions 6 7 3
We examined genes that were identified as significantly associated (P < 2.80 × 10 -6 ) with depression 6 7 4
using MAGMA 24 for interactions with prescribed medications using the Drug Gene Interaction classification system was used to determine the second level classification of each drug identified. We are grateful to the participants and research teams behind the Psychiatric Genomics Consortium, 6 9 2 UK Biobank and 23andMe. We thank the following members of the 23andMe Research Team: his advice on analysing the expression-weighted enrichment for brain cell-types. contact for all communication. All authors commented on the manuscript. The summary statistics for the genetic variants assessed in the meta-analysis (23andMe_307k, UK 7 3 6
Biobank, and PGC_139k) will be available alongside the final published manuscript. The raw genetic and phenotypic UK Biobank data used in this study, which were used under license, , e t a l . 
